BSE: 500009 | NSE: AMBASARABH | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Ambalal Sarabhai Enterprises Ltd is a below average quality company.
The key valuation ratios of Ambalal Sarabhai Enterprises Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Ambalal Sarabhai Enterprises Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -3.4% | 106.9% | -24.6% | 7% | -7.4% | 37.6% | -19.1% | 8.7% | 9.6% | 6% | - |
| Value Creation Index ⓘ | -1.2 | 6.6 | -2.8 | -0.5 | -1.5 | 1.7 | -2.4 | -0.4 | -0.3 | -0.6 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 15.3 | 7 | 1.5 | 0.9 | 0 | 0 | 0 | 0.1 | 3.7 | 3.8 | 2 |
| Sales YoY Gr. | - | -54.2% | -78.4% | -39.1% | -100% | NA | NA | NA | 2,753.9% | 2.7% | - |
| Adj EPS ⓘ | -2.2 | -2.5 | -2 | -1.4 | -0.5 | 0.7 | -0.6 | -0.9 | 0.6 | 0.3 | 1.2 |
| YoY Gr. | - | NA | NA | NA | NA | NA | -189.4% | NA | NA | -42.4% | - |
| BVPS (₹) ⓘ | 0.4 | 6.4 | 3.9 | 3.7 | 3.2 | 5.3 | 4 | 4.4 | 4.9 | 5.3 | 5.9 |
| Adj Net Profit ⓘ | -16.9 | -19.3 | -15.2 | -10.8 | -3.9 | 5.1 | -4.5 | -7.1 | 4.6 | 2.6 | 9 |
| Cash Flow from Ops. ⓘ | -12.1 | -69.4 | -3.7 | -12.7 | -3.3 | -4.5 | -10.4 | -7.8 | 1.5 | -3.8 | - |
| Debt/CF from Ops. ⓘ | -2.5 | -0.4 | -6 | -0.9 | -3.4 | -2.4 | -1.1 | -1.3 | 7.6 | -2.6 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -14.3% | NA | NA | 2.7% | ||||
| Adj EPS ⓘ | NA | NA | NA | -42.4% | ||||
| BVPSⓘ | 32.8% | 10.2% | 9.4% | 6.5% | ||||
| Share Price | 26.3% | 34% | 23.2% | 15.6% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -218.3 | -74.2 | -38.5 | -36.6 | -14.5 | 15.5 | -12.7 | -22.2 | 12.7 | 6.7 | 20.7 |
| Op. Profit Mgn % ⓘ | -78 | -307.6 | -857.7 | -2256.1 | 0 | 0 | 0 | -4366.1 | -139.1 | -125.5 | -145.5 |
| Net Profit Mgn % ⓘ | -110.6 | -275.8 | -1005.9 | -1167.3 | 0 | 0 | 0 | -5600.7 | 122.9 | 68.2 | 359.7 |
| Debt to Equity ⓘ | 9.6 | 0.6 | 0.7 | 0.4 | 0.5 | 0.3 | 0.4 | 0.3 | 0.3 | 0.3 | 0 |
| Working Cap Days ⓘ | 1,498 | 2,601 | 7,568 | 10,983 | 0 | 0 | 0 | 1,12,016 | 3,670 | 3,631 | 834 |
| Cash Conv. Cycle ⓘ | -89 | -14 | -248 | -905 | 0 | 0 | 0 | -1,715 | -931 | -904 | -95 |
Return on Equity has increased versus last 3 years average to 20.60%
Sales growth has been subdued in last 3 years 0.00%
Net Profit has been subdued in last 3 years 0.00%
Sales growth is not so good in last 4 quarters at -10.26%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1.2 | 1.7 |
| TTM Sales (₹ Cr.) | 2.5 | 183 |
| BVPS (₹.) ⓘ | 5.9 | 18.3 |
| Reserves (₹ Cr.) ⓘ | -32 | 64 |
| P/BV ⓘ | 9.50 | 3.05 |
| PE ⓘ | 48.53 | 32.51 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 37.54 / 77.70 |
| All Time Low / High (₹) | 1.57 / 80.00 |
| Market Cap (₹ Cr.) | 428 |
| Equity (₹ Cr.) | 76.6 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15 | 7 | 2 | 1 | 0 | 0 | 0 | 0 | 4 | 4 |
| Operating Expenses ⓘ | 27 | 29 | 22 | 22 | 9 | 8 | 38 | 6 | 9 | 9 |
| Manufacturing Costs | 1 | 3 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| Material Costs | 13 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 4 | 4 |
| Employee Cost | 8 | 10 | 7 | 4 | 4 | 3 | 3 | 3 | 2 | 2 |
| Other Costs ⓘ | 4 | 12 | 13 | 16 | 4 | 4 | 34 | 3 | 3 | 3 |
| Operating Profit ⓘ | -12 | -22 | -21 | -21 | -9 | -8 | -38 | -6 | -5 | -5 |
| Operating Profit Margin (%) | -79.0% | -309.0% | -1,364.4% | -2,256.1% | - | - | - | -4,366.1% | -139.0% | -126.0% |
| Other Income ⓘ | 14 | 96 | 7 | 24 | 6 | 25 | 30 | 40 | 11 | 8 |
| Interest ⓘ | 8 | 2 | 3 | 1 | 1 | 0 | 1 | 0 | 0 | 2 |
| Depreciation ⓘ | 3 | 15 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -30 | -1 | 0 |
| Profit Before Tax ⓘ | -9 | 58 | -19 | 2 | -3 | 16 | -9 | 3 | 4 | 1 |
| Tax ⓘ | 0 | 12 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | -2 |
| Profit After Tax | -9 | 46 | -21 | -1 | -4 | 16 | -9 | 3 | 4 | 3 |
| PAT Margin (%) | -60.0% | 653.9% | -1,360.6% | -155.0% | - | - | - | 2,318.5% | 110.9% | 67.8% |
| Adjusted EPS (₹) | -1.2 | 6.0 | -2.7 | -0.2 | -0.5 | 2.0 | -1.2 | 0.4 | 0.5 | 0.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 3 | 49 | 30 | 29 | 25 | 40 | 31 | 34 | 38 | 40 |
| Share Capital ⓘ | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
| Reserves ⓘ | -73 | -28 | -46 | -48 | -52 | -36 | -46 | -43 | -39 | -36 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 30 | 30 | 22 | 11 | 11 | 11 | 11 | 10 | 11 | 10 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 30 | 30 | 22 | 11 | 11 | 11 | 11 | 10 | 11 | 10 |
| Trade Payables | 12 | 9 | 11 | 21 | 20 | 19 | 18 | 17 | 16 | 16 |
| Others Liabilities ⓘ | 124 | 69 | 50 | 68 | 80 | 53 | 38 | 21 | 13 | 14 |
| Total Liabilities ⓘ | 170 | 157 | 113 | 128 | 136 | 123 | 98 | 82 | 78 | 80 |
Fixed Assets | ||||||||||
| Gross Block | 96 | 76 | 19 | 18 | 18 | 18 | 18 | 17 | 17 | 17 |
| Accumulated Depreciation | 54 | 55 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 4 |
| Net Fixed Assetsⓘ | 43 | 21 | 16 | 15 | 15 | 14 | 14 | 13 | 13 | 13 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 56 | 83 | 76 | 67 | 67 | 65 | 35 | 26 | 26 | 25 |
| Inventories | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Receivables | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Equivalents | 3 | 7 | 5 | 6 | 4 | 4 | 9 | 5 | 3 | 3 |
| Others Assetsⓘ | 63 | 46 | 16 | 40 | 50 | 39 | 40 | 38 | 36 | 39 |
| Total Assets ⓘ | 170 | 157 | 113 | 128 | 136 | 123 | 98 | 82 | 78 | 80 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -12 | -69 | -4 | -13 | -3 | -5 | -10 | -8 | 2 | -4 |
| PBT ⓘ | -9 | 58 | -19 | 2 | -3 | 16 | -9 | 3 | 4 | 1 |
| Adjustment ⓘ | -1 | -73 | 5 | -15 | -2 | -22 | 2 | -1 | -6 | -4 |
| Changes in Working Capital ⓘ | 2 | -50 | 10 | 18 | 6 | 2 | -2 | -9 | 4 | 0 |
| Tax Paid ⓘ | -3 | -3 | 0 | -18 | -4 | 0 | 0 | -1 | -1 | -1 |
| Cash Flow From Investing Activity ⓘ | 13 | 75 | 9 | 26 | 2 | 5 | 16 | 21 | 1 | 3 |
| Capex | 12 | 100 | 1 | 14 | 0 | 0 | 11 | 19 | 0 | 0 |
| Net Investments | 0 | -27 | 7 | 9 | 0 | 0 | 3 | 0 | -9 | 0 |
| Others ⓘ | 1 | 2 | 1 | 3 | 2 | 5 | 1 | 2 | 9 | 4 |
| Cash Flow From Financing Activityⓘ | -1 | -3 | -8 | -12 | 0 | 0 | 0 | -16 | -4 | 0 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | -4 | -2 | -3 | -1 | -1 | 0 | -1 | 0 | -2 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 3 | -1 | -6 | -11 | 0 | 0 | 0 | -16 | -1 | 1 |
| Net Cash Flow ⓘ | 0 | 3 | -3 | 1 | -1 | 0 | 5 | -3 | -2 | 0 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -118.49 | 175.78 | -52.03 | -4.89 | -14.52 | 47.82 | -26.43 | 9.17 | 11.49 | 6.61 |
| ROCE (%) | -3.41 | 106.93 | -24.55 | 7.02 | -7.42 | 37.59 | -19.12 | 8.67 | 9.58 | 5.96 |
| Asset Turnover Ratio | 0.09 | 0.05 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0.05 | 0.05 |
| PAT to CFO Conversion(x) | N/A | -1.5 | N/A | N/A | N/A | -0.31 | N/A | -2.67 | 0.5 | -1.33 | Working Capital Days |
| Receivable Days | 56 | 36 | 0 | 0 | 0 | 0 | 0 | 431 | 22 | 33 |
| Inventory Days | 35 | 72 | 52 | 43 | 0 | 0 | 0 | 0 | 2 | 0 |
| Payable Days | 368 | 1,069 | 3,711 | 0 | 0 | 0 | 0 | 0 | 1,660 | 1,561 |
Ambalal Sarabhai Enterprises is a Baroda-based pharmaceutical manufacturing company which was incorporated in 1977. It is one of the company belonging to the Sarabhai Group. The Group's principal activity is manufacture and marketing of pharmaceutical products and bulk drugs. The company's plants are located at Vadodara and Ahmedabad.
History of the company:-
1977: The company was incorporated on June 27, as a private limited company. It was converted into a public limited company on December 29, 1980. The objects are manufacture of drugs and pharmaceuticals, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials. The company also carries on industrial research and consultancy services.
(a) Elscope Private (Elscope) became the owner of the undertaking and business of Sarabhai Chemicals, Sarabhai Machinery and Bakubhai Ambalal; and
(b) Ofisade Private Limited (Ofisade) became the owner of undertakings and business of Sarabhai M Chemicals, Swastik Household and Industrial Products, Systronics, Telerad, ORG Systems and Operations Research Group, Packart, Cotton & Cloth and WIPS, Sarabhai Research Centre and Sarabhai Electronics Research Centre.
As a part of the reorganization, the company also acquired from Shahibag Entrepreneurs Pvt. Ltd, the entire share capital of Himinonic Detergents Industries Pvt. Ltd. (Him ionic) and from Kalindi Investments Pvt. Ltd., the entire share capital of Surac Holdings Pvt. Ltd. (Surac). There upon Wadi Holdings Pvt.Ltd., the respective subsidiaries of Himionic and Surac, became subsidiaries of the company.
The acquisition of the undertakings from Elscope became effective from 1st July.
1978:The acquisition of the undertakings from Ofisade became effective from May 16, but in terms of the sale agreement. the company issued further 11% Non-Convertible bonds of the face value of Rs.166 lakh to the holding companies of Sarabhai Enterprises and their subsidiaries to convert demand liabilities of that amount into deferred credits.
1981:
1982:
It was proposed to amalgamate with the company Swastik Household& Industrial Products P. Ltd, Ambernath (Maharashtra), SM Chemicals & Electronics P Ltd. Kandivli, Bombay and WhitcoLtd, with effect from July 1.
1983:
The Scheme of Amalgamation of Swastik Household Industrial Products Pvt. Ltd. (SHIP, Pvt. Ltd) and S.M. Chemicals & Electronics Pvt. Ltd. (SMCEPL) with the company was sanctioned by the Bombay High Court and approval from the Gujarat High Courtwas received on May 12, 1987.
1984:
The company issued 15% secured non-convertible debentures for Rs 10 crore. The issue was substantially over-subscribe and after obtaining consent to retain the excess upto 50% of the issue debentures of Rs.15 crores were allotted on February 1, 1985.
1985:
In a bid to gain access to the latest innovations in various fields of technological specialisation achieved by world leaders in the field of bulk drugs and pharmaceuticals, electronics and synthetic detergents, a scheme of reorganisation of Ambalal Sarabhai Enterprises (ASE) Ltd was evolved. Under this scheme it was proposed to divide with effect from July 1, the existing operations of ASE between ASE and its two subsidiaries to be named Sarabhai Electronics Ltd, and Sarabhai Surfactants,Ltd and give their shares to the existing shareholders of ASE.
1986:
The Scheme of Amalgamation for the merger of ASE, of its subsidiaries Himionic holdings Ltd, Wadi Holdings, Ltd, Surac Holdings, Ltd, Perion Holdings Ltd, Wadi Financiers and Investments Ltd, and Shahibag Investments Ltd with effect from July 1, was sanctioned by the High Courts of Gujarat and Bombay.
1987:
The Gujarat High Court gave its sanction for the Scheme of Amalgamation on December 24.
1988:
The company entered into an understanding with US-based Bristol-Myers Squibb Corporation for technical know-how in the manufacture of pharmaceuticals and penicillin. This was done with a view to takeover as a going concern the existing undertaking of Synbiotics Ltd for the manufacture of bulk drugs because the company had suffered a severe setback due to non-availability of working funds resulting in under utilisation of capacity.
1989:
The company entered into technical collabortion agreements with Avesta (Sweden) and Pannevis (the Netherlands) for the manufacture of special process equipments and screen making equipment.
1996:
The company obtained industrial licences for the manufacture of: (i) fatty acids from minor edible oils, (ii) Sorbitol, and (iii) increcal (cycocel technical) an agrochemical. Letters of Intent were in hand for the manufacture of (i) chlorine and Its salts and (ii) screen making equipment. Industrial licence for the manufacture of (i) electronic measuring and testing instrument, (ii) closed cirucuit television systems and (iii sSpecial process equipment including vacuum dryers, sterilisers, evaporators, crystallisers, heat exchangers, etc. were in the process of being endorsed in the name of the company. The company's application for the manufacture of computer peripheralsand micro-processors was pending with the government.
2007:
Ambalal Sarabhai Enterprises Ltd appointed B S Bohra as additional director of the company with effect from April 20, 2007.
The Group operates in two segments: pharmaceuticals and electronics.segements. It further has two divisions - Systronics Division - Systronics Division has been contributing and delivering some of the import substitute products like Double Beam UV - Visible Spectrophotometers, Photo flourimeters, etc. Further, to make the complete range available under one roof, Systronics division has entered in to strategic tie-up with some of the local and foreign manufacturers with co-branding or marketing their products like Gas Chromatographs, HPLC, Atomic Absorption spectrophotometers, FTIR, Amino Acid Analyser.
Telerad Division - The company also has Telerad division, which is one of the oldest representatives of Sony in India promoting broadcast and professional video/audio products for more than three decades. This division has expanded its services through eight branch offices in different locations of India. Telerad division has also extended its services in the area of design, system supply, installation, integration, training, maintenance and supply of spares. The company exports its products to regions such as Japan, Europe, USA, Africa, and Middle East. Some of its subsidiaries include Synbiotics Ltd., Haryana Containers Ltd., Asence Inc. USA, and Mautik Exim Ltd.
Products Offered:
The company has following products offering
1) Therapeutic, bulk drugs and veterinary segments.
2) ASE`s formulations in the therapeutic segment include anti-infective, analgesic, anti-inflammatory, nutritional, oncological, cardiovascular, gastrointestinal, and anti diabetic products to name a few.
3) The company`s products in the bulk drug segment include Acenocoumarol, Amphotericine, Ascorbic Acid, Canrenone and Carbamazeine among others. ASE, in the animal health care market, offers a wide range of therapeutic and nutritional formulations for livestock, poultry and pets.
Subsidiaries of the Company:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
